TISSUEGENE
TissueGene is a Maryland-based biopharmaceutical company focused on developing regenerative therapies for the treatment of various orthopedic disorders. Founded in 1999, the company’s core technology employs a form of cell therapy to deliver therapeutic proteins directly to localized areas of damaged tissue. The sustained expression of such proteins initiates rapid repair of injured tissue without the need for invasive surgical procedures. TissueGene is currently developing four product candidates, TG-C, TG-B, TG-D, and TG-N for the regeneration of cartilage, bone, disc, and nerve, respectively. The company's lead product candidate, TG-C, has been developed for treating osteoarthritis of the knee and is currently in Phase II trials in the US and in Phase III trials in Korea.
TISSUEGENE
Social Links:
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
1999-01-01
Address:
Rockville, Maryland, United States
Country:
United States
Website Url:
http://www.tissuegene.com
Total Employee:
11+
Status:
Active
Contact:
(301)921-6000
Email Addresses:
[email protected]
Total Funding:
124.73 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Apple Mobile Web Clips Icon Google Font API Google Analytics LetsEncrypt Amazon SSL By Default Google Universal Analytics
Similar Organizations
Acceleron Pharma
Acceleron is a biopharmaceutical company engaged in developing, manufacturing and commercializing novel biotherapeutics.
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Panoptes Pharma
Developing innovative small molecule drugs to treat eye diseases with high unmet medical need.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Vital Therapies
Vital Therapies is a biotech company focused on developing a cell-based therapy targeting the treatment of acute liver failure.
Current Employees Featured
Stock Details
Official Site Inspections
http://www.tissuegene.com Semrush global rank: 7.7 M Semrush visits lastest month: 723
- Host name: ec2-174-129-30-187.compute-1.amazonaws.com
- IP address: 174.129.30.187
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "TissueGene"
TissueGene - Crunchbase Company Profile & Funding
TissueGene is a Maryland-based biopharmaceutical company focused on developing regenerative therapies for the treatment of various orthopedic disorders. Founded in 1999, the …See details»
Kolon TissueGene, Inc. (950160)
Developing Advanced Cell Therapies for the Treatment of Orthopedic Disorders and Unmet Medical Needs. Kolon TissueGene is a Maryland-based biopharmaceutical company …See details»
Kolon TissueGene, Inc. Information - RocketReach
The NAICS codes for Kolon TissueGene, Inc. are [32541, 32, 3254, 325]. What is the SIC code for Kolon TissueGene, Inc.? The SIC codes for Kolon TissueGene, Inc. are [283, 28]. Top …See details»
Kolon TissueGene Company Description - Stock Analysis
4 days ago Kolon TissueGene, Inc. was formerly known as TissueGene, Inc. and changed its name to Kolon TissueGene, Inc. in March 2018. The company was founded in 1999 and is …See details»
Global KOLON | KOLON GROUP
KOLON TISSUEGENE, INC. 9713 KEY WEST AVENUE #300, ROCKVILLE, MD 20850, USA. Tel : 1-301-921-6000. Contact Us. Famliy Site. KOLON Industries KOLON Global KOLON …See details»
TissueGene - Tech Stack, Apps, Patents & Trademarks - Crunchbase
TissueGene is a biopharmaceutical company focused on developing regenerative therapies for the treatment of various orthopedic disorders. New. Resources. Advanced Search. Start Free …See details»
Drug Delivery | Tissuegen | Dallas
TissueGen solves for unmet needs through the development of transformative drug delivery technologies that reduce treatment burden and improve clinical outcomes. We create life …See details»
Korean :: Kolon TissueGene, Inc. (950160)
This information—including product information—is intended only for residents of the United States. The products discussed on this site may have different labeling in different countries.See details»
Kolon TissueGene, Inc. (Kolon TissueGene, Inc.) - 药物管线_专利_临 …
了解Kolon TissueGene, Inc. (Kolon TissueGene, Inc.)公司的药物管线，治疗领域，技术平台，以及它的6项临床试验, 3篇新闻和2篇文献，疾病领域:神经系统疾病，免疫系统疾病，技术平台: …See details»
Moon Jong Noh - CEO @ TissueGene - Crunchbase Person Profile
Moon Noh is the Chief Executive Officer at TissueGene, Inc. He attended the Korea Advanced Institute of Science and Technology. Jobs. Edit Jobs Section. Number of Current Jobs 1. ...See details»
KOLON TISSUEGENE COMPLETES PATIENT DOSING IN TWO …
Jul 11, 2024 Kolon TissueGene, Inc., is an advanced cell therapies company that has developed a first-in-class cell and gene therapy targeting OA of the knee. The Company's lead product, …See details»
KOLON LIFE SCIENCE, Inc. - Drug pipelines, Patents, Clinical trials ...
Jan 23, 2025 Abstract Osteoarthritis (OA) is the most common form of arthritis, characterized by cartilage destruction, pain and inflammation in the joints. Existing medications can provide …See details»
Kolon TissueGene’s osteoarthritis therapy TG-C ... - 조선일보
Jul 12, 2024 Kolon TissueGene’s TG-C, a new gene therapy drug for osteoarthritis, has completed the final phase of the U.S. Food and Drug Administration’s (FDA) phase 3 clinical …See details»
IR Material :: Kolon TissueGene, Inc. (950160)
This information—including product information—is intended only for residents of the United States. The products discussed on this site may have different labeling in different countries.See details»
Kolon Tissuegene Announces Plans To Resume US Phase III
ROCKVILLE, Md., April 13, 2020 /PRNewswire/ -- Kolon TissueGene, Inc. (the “Company”), a leader in advanced cell and gene therapies, announced today that the Clinical Hold issued by …See details»
TissueGene-C induces anti-inflammatory activity and M2 …
5 World Health Organization Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging, UniversitedeLiege, Li ege, Belgium ARTICLE INFO ... TissueGene-C (TG …See details»
KOLON TISSUEGENE COMPLETES PATIENT DOSING IN TWO …
Jul 11, 2024 Kolon TissueGene, Inc., is an advanced cell therapies company that has developed a first-in-class cell and gene therapy targeting OA of the knee. The Company’s lead product, …See details»
TissueGene Inc Stock Price Today | KQ: 950160 Live - Investing.com
Kolon TissueGene, Inc. was formerly known as TissueGene, Inc. and changed its name to Kolon TissueGene, Inc. in March 2018. The company was founded in 1999 and is headquartered in …See details»
Tissuegene-c induces long-term analgesic effects through …
Purpose: TissueGene-C (TG-C), comprising human allogeneic chondrocytes and irradiated GP2-293 cells manipulated to overexpress transforming growth factor-β1 (TGF-β1), has been …See details»
TissueGene-C induces anti-inflammatory activity and M2 …
Osteoarthritis (OA) is the most common form of degenerative joint disease that commonly affects the knees, hips and hands. OA is a mechano-inflammatory disease characterized by low …See details»